910232-84-7
910232-84-7
Chemical Structure
CGI-1746
- CAS No.: 910232-84-7
- Formula:C34H37N5O4
- Molecular Weight:579.69
IUPAC Name: 4-(tert-butyl)-N-(2-methyl-3-(4-methyl-6-((4-(morpholine-4-carbonyl)phenyl)amino)-5-oxo-4,5-dihydropyrazin-2-yl)phenyl)benzamide
InChIKey: JIFCFQDXHMUPGP-UHFFFAOYSA-N
SMILES: O=C(C1=CC=C(C=C1)C(C)(C)C)NC2=CC=CC(C(N=C3NC4=CC=C(C=C4)C(N5CCOCC5)=O)=CN(C3=O)C)=C2C
Biological Activity: CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM.
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
CGI-1746 | 99.25% | CGI-1746 is a potent and highly selective inhibitor of the Btk with IC50 of 1.9 nM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CHMFL-BTK-01 | CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
RN941 | RN941 is a BTK inhibitor. RN941 is applicable to research related to rheumatoid arthritis and B-cell malignancies. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DD-03-171 | 98.72% | DD-03-171 is a PROTAC BTK degrader. DD-03-171 inhibits mantle cell lymphoma (MCL) cell proliferation (IC50 = 5.1 nM) and prolongs the survival of mice bearing a lymphoma PDX model by degrading BTK, IKFZ1, and IKFZ3. DD-03-171 also inhibits platelet function and thrombosis. (Pink: BTK ligand 9 (HY-168292); Black: linker (HY-28875); Blue: Thalidomide-NH-CH2-COOH (HY-131717)). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Hedgehog IN-4 | Hedgehog IN-4 is a benzamide derivative and also an inhibitor of the Hedgehog signaling pathway, with an IC50 of 0.050 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GDC-0834 | 98.05% | GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GDC-0834 Racemate | GDC-0834 Racemate is the racemic form of GDC-0834 (HY-15427). GDC-0834 is an orally active selective, potent, and reversible BTK inhibitor with an IC50 of 5.9 nM. GDC-0834 demonstrates pBTK-Tyr223 inhibition in mice and rats. GDC-0834 can be used for research of rheumatoid arthritis (RA). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GDC-0834 (S-enantiomer) | GDC-0834 (S-enantiomer) is the S-enantiomer of GDC-0834. GDC-0834 is a potent and selective BTK inhibitor. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BTK ligand 9 | BTK ligand 9 is a target protein ligand for BTK and can be used to synthesize PROTAC DD-03-171 (HY-122830). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CGI 560 | CGI 560 is an inhibitor for Bruton's tyrosine kinase (BTK) with an IC50 of 400 nM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DM175 | DM175 is a partial agonist of FXR. DM175 binds to the ligand-binding domain of FXR and induces the outward movement of Trp454. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
